ClinicalTrials.gg
CompletedNCT05253053Updated Jun 12, 2025

To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

A Phase 1/2 interventional study of TT-00420 and Combination Product: Atezolizumab in Advanced Solid Tumor, Cholangiocarcinoma and Biliary Tract Cancer, sponsored by TransThera Sciences (Nanjing), Inc.. Completed at 9 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-12.

Sponsored by TransThera Sciences (Nanjing), Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
84
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 230 studies in Cholangiocarcinoma with a site in China — 114 open to participants now, 125 under way, 12 of them phase 3. Cholangiocarcinoma · China.

Enrollment
64th of 191
84 · median 51
Started
2022
with 21 others
Phase 1/2
11 of 230
6 open now
Registered
99th of 230
by date

Among the 230 studies in Cholangiocarcinoma with a site in China, this one is the 64th largest by enrollment of the 191 interventional ones that give a count, is one of 22 that started in 2022, is one of 11 in phase 1/2, and was the 99th registered.

Cholangiocarcinoma

825 studies on the registry are indexed under Cholangiocarcinoma; 288 are open to participants now.

Browse Cholangiocarcinoma studies →

Open to participants now

114 of the 230 studies in Cholangiocarcinoma with a site in China are open now. Recruiting first, the newest first:

109 more — sign in →

All 114 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 211 Cholangiocarcinoma studies recruiting now, 141 (67%) set no upper age limit and 49 (23%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 230 studies in Cholangiocarcinoma with a site in China, or all of them as a file.
02

Study summary

This is a Phase Ib/II, multicenter, open-label study to evaluate the safety and preliminary efficacy of TT-00420 tablet, as monotherapy or in combination regimens, in patients with advanced solid tumors (solid tumor, BTC and TNBC).

Read the detailed description

Study consists of three arms, Arm A is a Phase Ib/II study of TT-00420 tablet monotherapy, Arm B is a Phase Ib/II study of TT-00420 tablet in combination with atezolizumab (Tecentriq®), and Arm C is a Phase Ib/II study of TT-00420 tablet in combination with nab-paclitaxel (Abraxane®).

Arm A: TT-00420 Tablet Monotherapy Phase Ib will enroll patients with preferred indications including advanced cholangiocarcinoma, small cell lung cancer, HER2-negative breast cancer including TNBC, bladder cancer, prostate cancer, thyroid cancer, gastric cancer, gallbladder cancer and other advanced solid tumors to receive TT-00420 monotherapy. Phase Ib will be a dose escalation study of TT-00420 in combination, guided by 3+3 design, to determine a Recommended Phase 2 Dose (RP2D). Based on preliminary efficacy results, Phase II will enroll additional patients in select indications to evaluate the efficacy of TT-00420 monotherapy.

Arm B: TT-00420 tablet in combination with atezolizumab (Tecentriq®) Arm B will enroll patients with advanced biliary tract cancer. Phase Ib will be a dose escalation study of TT-00420 in combination with nab-paclitaxel, guided by 3+3 design, to determine a Recommended Phase 2 Dose (RP2D). Phase II will enroll additional patients with advanced biliary tract cancer to further evaluate the efficacy of the combination regimen.

Arm C: TT-00420 tablet in combination with nab-paclitaxel (Abraxane®) Arm C will enroll patients with advanced triple-negative breast cancer (TNBC). Phase Ib will be a dose escalation study of TT-00420 in combination with nab-paclitaxel, guided by 3+3 design, to determine a Recommended Phase 2 Dose (RP2D). Phase II will enroll additional patients with advanced TNBC to further evaluate the efficacy of the combination regimen.

03

Conditions studied

  • Advanced Solid Tumor
  • Cholangiocarcinoma
  • Biliary Tract Cancer
  • HER2-negative Breast Cancer
  • Triple Negative Breast Cancer
  • Small-cell Lung Cancer
  • Bladder Cancer
  • Prostate Cancer
  • Thyroid Cancer
  • Gastric Cancer
  • Gallbladder Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥ 18 years of age
  2. Arm A:Histopathological or documented locally advanced or and solid tumors(including but not limited to advanced cholangiocarcinoma, small cell lung cancer, -negative breast cancer including TNBC, bladder cancer, prostate cancer, thyroid cancer, gastric cancer, gallbladder cancer and other advanced solid tumors.

    Arm B:Histopathological or cytologically documented locally advanced or metastatic and Unresectable advanced biliary tract malignant tumors (except ampullary carcinoma).

    Arm C:

    • Histopathological invasive advanced TNBC with triple-negative receptor status that meets the institution standards was proved ER or PR by IHC (positive tumor nucleus\<10% )
    • HER2-negative (ASCO-CAP guideline [Wolff A C, 2018] )
  3. Received all currently available standard treatments (unless the treatment is , intolerable, or unavailable for any reason)
  4. At least one as defined by V1.1 criteria for solid tumors
  5. (ECOG) performance status ≤ 2
    1. Adequate organ and bone marrow function(without receiving any hematopoietic growth factor, blood or therapy within 1 week before the first dose.

      • Complete blood count (CBC):

        • (ANC)≥ 1.5 × 109/L
        • (Hgb)≥ 9 g/dl
        • Platelets(Plt)≥ 75 × 109/L
      • Liver function:

        • /SGOT and ALT/SGPT ≤ 2.5 x (ULN) or ≤ 5.0 × ULN if liver metastases are present .
        • Total ≤ 1.5 × ULN or direct bilirubin\<ULN (if total bilirubin>1.5 ULN).
        • Patients with hepatocellular carcinoma (HCC) and BTC: A or B (Score ≤ 7).
      • Renal fuction:

        • serum creatinine ≤ 1.5 × ULN or Calculated 24-hour clearance ≥ 50 mL/min ( formula).
  6. Must agree to take sufficient methods to avoid pregnancy during the study and until at least 6 months after ceasing study treatment
  7. Able to sign and comply with the protocol

Exclusion criteria

Exclusion Criteria:

Patients who meet one or more of the following criteria will not be included in this study:

  1. Women who are pregnant or lactating
  2. Women of (WOCBP) who do not use adequate
  3. Patients with any hematologic , including leukemia (any form), lymphoma, and multiple myeloma
  4. Patients with a history of

    • primary central nervous system tumors or
    • carcinomatous meningitis (also known as ). Note: Patients with treated that are off and have been clinically stable for 28 days are eligible for enrollment.
  5. Impaired cardiac function or significant diseases, including but not limited to any of the following:

    • (LVEF) \< 45% as determined by multigated acquisition (MUGA) scan or echocardiogram (ECHO)
    • Congenital long syndrome
    • QTcF ≥ 450 msec on screening
    • Unstable angina pectoris ≤ 3 months prior to starting study drug
    • Acute myocardial infarction ≤ 3 months prior to starting study drug
  6. Patients who are currently receiving treatment with medication that has known risk to prolong the QT interval or induce Torsades de Pointes, and the treatment cannot either be discontinued or switched to a different medication prior to starting study drug.
  7. Patients with impairment of gastrointestinal (GI) function, or GI disease that may significantly alter the absorption of TT-00420
  8. Patients who have received chemotherapy, targeted therapy, or immunotherapy ≤ 4 weeks (6 weeks for nitrosourea or mitomycin-C) prior to starting study drug or who have not recovered from side effects of such therapy
  9. Patients who have undergone major surgery or wide field radiotherapy ≤ 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy
  10. Patients who are currently receiving treatment with strong inhibitors or inducers ≤ 2 weeks prior to starting study drug.
  11. Patients who have used of proton pump inhibitors (PPIs) within 4 days or histamine H2 blockers within 2 days prior to starting study drug
  12. (HIV) positive
  13. Patients with active infection (HBV DNA copy number ≥ ) and/or infection (HCV RNA copy number ≥ ULN)
  14. Patients with active tuberculosis
  15. Has received a live-virus vaccination within 30 days of planned first dose Note:Seasonal flu and COVID-19 vaccines are permitted before enrollment at least 7 days.
  16. Patients with a history of medical conditions, treatment, or abnormal laboratory tests that could affect the results of the study, interfere with study participation and compliance per investigator's judgment
  17. 【Note】:The following three types of patients may be enrolled after being determined by the sponsor:

    ①Patients who have received emergency, low-dose, systemic therapy (for example, one-time dexamethasone administration for vomiting);

    ② Patients who need steroid prophylaxis and have a history of intravenous contrast agent allergic reactions should use MRI for baseline and follow-up tumor assessment;

    ③The use of inhaled corticosteroids to treat , the use of mineralocorticoids (such as fludrocortisone) to treat patients with orthostatic hypotension and the use of low-dose supplementary corticosteroids to treat adrenal insufficiency are permitted.

    Arm B: TT-00420 tablet in combination with Atezolizumab Injection (Tecentriq ®): Subjects who meet one or more of the following criteria are also not allowed to participate in this study.

  18. A history of severe allergies, immune stress, or other reactions to chimeric or humanized antibodies or fusion proteins.
  19. Known to have hypersensitivity or allergies to any ingredient of Chinese hamster ovary cells or atelizumab injection.
  20. History of diseases, including but not limited to myasthenia gravis, autoimmune myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, and antiphospholipid syndrome related Vascular thrombosis, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis or glomerulonephritis.

    【Note】The following two types of patients may be enrolled after being determined by the sponsor: ① Patients who have a history of autoimmune hypothyroidism but have stable doses of thyroid replacement hormone therapy; ② Patients who use stable doses of insulin therapy to control type I diabetes may can be enrolled.

  21. Patients who have a history of allogeneic stem cell or solid organ transplantation.
  22. Patients who have a history of non-specific pulmonary fibrosis, tissue pneumonia (such as: bronchiolitis obliterans, unknown tissue pneumonia), drug-induced pneumonia, or active pneumonia showed by chest CT scan.

    【Note】radiation pneumonitis (fibrosis) exist in the radiation area can be enrolled.

  23. Patients who have received systemic immunostimulatory drugs therapy (including but not limited to interferon or IL-2) ≤ the shorter one of 4 weeks or 5 half-lives of immunostimulatory drugs.
  24. Patients who have received systemic corticosteroids or other systemic immunosuppressive drugs (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, and Tumor Necrosis Factor (TNF)) within 2 weeks prior to starting study.
Terms in these criteria, in plain language(33)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Arm A: TT-00420 Tablet Monotherapy

    TT-00420 tablets will be administered once daily in 21-day cycles. Dose escalation will be guided by a 3+3 design in Phase Ib to determine the recommended phase 2 dose (RP2D).

    Drug: TT-00420

  • Experimental
    Arm B: TT-00420 tablet in combination with Atezolizumab Injection (Tecentriq ®)

    TT-00420 tablets will be administered once daily in 21-day cycles. Atezolizumab(1200 mg/20 mL) will be administered intravenously on Day 1 of each 21-day cycle. Dose escalation will be guided by a 3+3 design in Phase Ib to determine the recommended phase 2 dose (RP2D).

    Drug: TT-00420 · Drug: Combination Product: Atezolizumab

  • Experimental
    Arm C: TT-00420 tablet in combination with nab-paclitaxel (Abraxane®)

    TT-00420 tablets will be administered once daily in 21-day cycles. Nab-paclitaxel 125 mg/m\^2 will be administered intravenously on Day 1 and 8 of each 21-day cycle. Dose escalation will be guided by a 3+3 design in Phase Ib to determine the recommended phase 2 dose (RP2D).

    Drug: TT-00420 · Drug: Combination Product: Nab-Paclitaxel

Interventions

  • TT-00420 tablet will be administered orally once daily per protocol defined schedule.

  • DrugCombination Product: Atezolizumab

    Drug page: Atezolizumab

    Atezolizumab would be administered via infusion on Day 1 of 21-day cycle

  • DrugCombination Product: Nab-Paclitaxel

    Drug page: Albumin-Bound Paclitaxel

    Nab-Paclitaxel would be administered via infusion on Day 1 and 8 of 21-day cycle

06

What researchers measure

Primary outcomes

  1. Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment

    As assessed per NCI Common Toxicity Criteria for Adverse Events, version 5.0

    Time frame: Up to 30 days from the last dose

  2. Dose limiting toxicity (DLT)

    Dose escalation cohorts are monitored and assessed using the NCI Common Toxicity Criteria for Adverse Events, version 5.0.

    Time frame: Up to 21 days from the first dose

Secondary outcomes

  1. Objective Response Rate (ORR)

    The proportion of subjects who achieved a complete response (CR) or a partial response (PR) based on RECIST version 1.1.

    Time frame: Through study completion, an average of 9 months

  2. Disease Control Rate (DCR)

    Defined as CR + PR + stable disease (SD) based on RECIST version 1.1.

    Time frame: Through study completion, an average of 9 months

  3. Duration of Objective Response (DOR)

    Duration of response for CR or PR based on RECIST version 1.1.

    Time frame: Through study completion, an average of 9 months

  4. Progression Free Survival (PFS)

    Time frame: From first study drug administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months

  5. Overall Survival (OS)

    Time frame: From first study drug administration until the date of death from any cause, assessed up to 24 months

  6. Area under the curve (AUC0-∞)

    Blood samples will be collected at designated time points for pharmacokinetic analysis of TT-00420

    Time frame: From Cycle 1 Day 1 to Cycle 2 Day 1 (each cycle is 21 days)

  7. Area under the curve (AUC0-t)

    Blood samples will be collected at designated time points for pharmacokinetic analysis of TT-00420

    Time frame: From Cycle 1 Day 1 to Cycle 2 Day 1 (each cycle is 21 days)

  8. Maximum observed concentration (Cmax)

    Blood samples will be collected at designated time points for pharmacokinetic

    Time frame: From Cycle 1 Day 1 to Cycle 2 Day 1 (each cycle is 21 days)

  9. Half-life (T1/2)

    Time frame: From Cycle 1 Day 1 to Cycle 2 Day 1 (each cycle is 21 days)

  10. Time to Maximum Concentration (Tmax)

    Time frame: From Cycle 1 Day 1 to Cycle 2 Day 1 (each cycle is 21 days)

  11. Volume of Distribution

    Time frame: From Cycle 1 Day 1 to Cycle 2 Day 1 (each cycle is 21 days)

Other outcomes

  1. Potential relationship between efficacy and biomarkers

    Evaluation of biomarkers, including but not limited to, FGFR2 alterations, PD-L1 expression, dMMR, MSI, TNBC subtype and TMB

    Time frame: Through study completion, an average of 9 months

  2. changes of main circulating metabolites of TT-00420 in plasma

    Time frame: Through study completion, an average of 9 months

07

Study locations

9 sites
  • The First Affiliated Hospital of Wannan Medical College
    Wuhu, Anhui, China
  • Henan Cancer Hospital
    Zhengzhou, Henan, China
  • Hunan Cancer Hospital
    Changsha, Hunan, China
  • Nanjing Drum Tower Hospital
    Nanjing, Jiangsu, China
  • Jilin Cancer Hospital
    Changchun, Jilin, China
  • Shandong Cancer Hospital
    Jinan, Shandong, China
  • Beijing Cancer Hospital
    Beijing, China
  • Peking University Third Hospital
    Beijing, China
  • Fudan Univisity Shanghai Cancer Center
    Shanghai, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Aug 2024, 28 months.

Of 40 phase 1/2 interventional studies under Cholangiocarcinoma, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 77. This study's 28 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2022
First posted
Feb 23, 2022
StartActual
Apr 13, 2022
Primary completionActual
Aug 31, 2024
CompletionActual
Aug 31, 2024
Last update
Jun 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05253053
Lead sponsor
TransThera Sciences (Nanjing), Inc.
Responsible party
Sponsor
First posted
Feb 23, 2022
Start date
Apr 13, 2022
Primary completion
Aug 31, 2024
Completion
Aug 31, 2024
Last update
Jun 12, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tinengotinib

Start the discussion